Comparative Pharmacology
Head-to-head clinical analysis: LEVAQUIN versus TROVAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVAQUIN versus TROVAN.
LEVAQUIN vs TROVAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination.
Trovan (trovafloxacin) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby blocking DNA replication and transcription.
LEVAQUIN (levofloxacin) 500 mg orally or intravenously once daily for most infections; 750 mg orally or intravenously once daily for more severe infections or complicated urinary tract infections.
200 mg IV once daily for 7-14 days for community-acquired pneumonia; 200 mg orally once daily for 7-14 days for acute exacerbation of chronic bronchitis
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged to 48-108 hours in severe renal impairment (CrCl <20 mL/min).
Terminal elimination half-life is approximately 10-12 hours in patients with normal renal function, supporting twice-daily dosing.
Primarily renal excretion as unchanged drug (approximately 87% in urine); fecal excretion accounts for <5% as unchanged drug and metabolites; biliary excretion is minimal.
Renal (approximately 60% unchanged) and fecal/biliary (approximately 35% as unchanged drug and metabolites).
Category C
Category C
Antibiotic (Fluoroquinolone)
Antibiotic (Fluoroquinolone)